{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:20:10Z","timestamp":1792408810986,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011746","name":"NOVARTIS Foundation (Japan) for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jtho.2019.06.023","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:59:27Z","timestamp":1562158767000},"page":"1753-1765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-3472","authenticated-orcid":false,"given":"Toshio","family":"Fujino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuta","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shimoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mitsudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2019.06.023_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/311029a0","article-title":"Molecular cloning of a new transforming gene from a chemically transformed human cell line","volume":"311","author":"Cooper","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2019.06.023_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2019.06.023_bib3","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non\u2013small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","article-title":"Somatic mutations lead to an oncogenic deletion of met in lung cancer","volume":"66","author":"Kong-Beltran","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/2159-8290.CD-15-0769","article-title":"MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker","volume":"5","author":"Ma","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.06.023_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.06.023_bib7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.06.023_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2019.06.023_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2019.06.023_bib10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2019.06.023_bib11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","article-title":"Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein","volume":"8","author":"Peschard","year":"2001","journal-title":"Molecular Cell"},{"key":"10.1016\/j.jtho.2019.06.023_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.06.023_bib16","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.cllc.2015.01.009","article-title":"Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation","volume":"16","author":"Jenkins","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.023_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib18","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2019.06.023_bib19","doi-asserted-by":"crossref","first-page":"120ra117","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2019.06.023_bib20","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2019.06.023_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jtho.2016.09.119","article-title":"Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 kipping","volume":"12","author":"Ou","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib22","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jtho.2017.02.017","article-title":"Mutation of MET Y1230 as an acquired mechanism of crizotinib resistance in NSCLC with MET exon 14 skipping","volume":"12","author":"Schrock","year":"2017","journal-title":"J\u00a0Thoracic Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib23","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-18-1640","article-title":"Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer","volume":"25","author":"Suzawa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib24","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1158\/1078-0432.CCR-18-0876","article-title":"Amplification of wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer","volume":"24","author":"Bahcall","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.21037\/atm.2017.03.64","article-title":"MET in human cancer: germline and somatic mutations","volume":"5","author":"Tovar","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2019.06.023_bib26","first-page":"5462","article-title":"A\u00a0novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase","volume":"63","author":"Sattler","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2019.06.023_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.lungcan.2015.10.020","article-title":"MET gene exon 14 deletion created using the CRISPR\/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor","volume":"90","author":"Togashi","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.023_bib29","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1158\/0008-5472.CAN-16-1944","article-title":"MET exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib30","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","article-title":"Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models","volume":"23","author":"Engstrom","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib31","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/JTO.0b013e31822591e9","article-title":"MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non\u2013small cell lung cancer according to MET alterations","volume":"6","author":"Tanizaki","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib32","doi-asserted-by":"crossref","unstructured":"Wolf J, Seto T, Han J-Y, et al. LBA52 Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METDex14 mutated advanced non-small cell lung cancer (NSCLC). Paper presented at: ESMO 2018 Congress. October 19, 2018; Munich, Germany.","DOI":"10.1093\/annonc\/mdy424.090"},{"key":"10.1016\/j.jtho.2019.06.023_bib33","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1016\/j.jtho.2018.08.300","article-title":"OA12.02 Updated antitumor activity of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer","volume":"13","author":"Drilon","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib34","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/j.jtho.2018.08.299","article-title":"OA12.01 Phase II data for the met inhibitor tepotinib in patients with advanced NSCLC and MET exon 14-skipping mutations","volume":"13","author":"Felip","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Garraway","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.06.023_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1383-5718(96)00121-0","article-title":"Mutations induced in male germ cells after treatment of transgenic mice with ethylnitrosourea","volume":"388","author":"Katoh","year":"1997","journal-title":"Mut Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1101\/gr.213546.116","article-title":"Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations","volume":"27","author":"Brammeld","year":"2017","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lungcan.2016.11.006","article-title":"Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations","volume":"102","author":"Dong","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.023_bib39","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jtho.2016.06.013","article-title":"Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping","volume":"11","author":"Heist","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2017.09.006","article-title":"Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping","volume":"113","author":"Zhang","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.023_bib41","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-10-4433","article-title":"A\u00a0drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients","volume":"71","author":"Tiedt","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.06.023_bib42","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1038\/s41467-018-07078-0","article-title":"Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors","volume":"9","author":"Fassunke","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2019.06.023_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2018.07.004","article-title":"Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient","volume":"123","author":"Ai","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.023_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-1-15","article-title":"P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia","volume":"1","author":"Cang","year":"2008","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtho.2019.06.023_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non\u2013small cell lung cancer: the why, the how, the who, the unknown, and the inevitable","volume":"103","author":"Reungwetwattana","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.06.023_bib46","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","article-title":"Acquired METD1228V mutation and resistance to MET inhibition in lung cancer","volume":"6","author":"Bahcall","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.06.023_bib47","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1158\/1078-0432.CCR-16-3273","article-title":"Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non\u2013small cell lung cancer","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419305519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419305519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:41:35Z","timestamp":1761561695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086419305519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1556086419305519"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2019.06.023","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}